Cardioselective β1-adrenergic blocker. Prepn: BE 859425; R. Jonas et al., US 4258062 (1978, 1981 both to E. Merck). Clinical pharmacology: A. E. Tattersfield et al., Br. J. Clin. Pharmacol. 18, 343 (1984); P. Dorow, U. T"onnesmann, Eur. J. Clin. Pharmacol. 27, 135 (1984). Binding study of (-)-form: A. J. Kaumann, H. Lemoine, Arch. Pharmacol. 331, 27 (1985). HPLC determn of enantiomers in plasma and urine: T. Suzuki et al., J. Chromatogr. 619, 267 (1993). Clinical evaluation in angina: R. S. Kohli et al., Eur. Heart J. 6, 845 (1985); in hypertension: F. R. Bühler et al., J. Cardiovasc. Pharmacol. 8, Suppl. 11, S122 (1986). Review of pharmacokinetics: J. Grevel et al., Clin. Pharmacokinet. 17, 53-63 (1989); of clinical efficacy in combination with hydrochlorothiazide: P. K. Zachariah et al., Clin. Ther. 15, 779-787 (1993). Clinical trial in chronic heart failure: CIBIS-II Investigators, Lancet 353, 9 (1999).
Antihypertensive.
β-Adrenergic Blocker; Antihypertensive; Aryloxypropanolamine Derivatives